Immunotherapies utilizing NK cells are attracting increasing attention in cancer treatment. Early clinical trials have shown promising results, demonstrating strong efficacy and safety profiles. NK cell therapies have shown notable clinical effectiveness, with response rates ranging from 40% to 80% in certain blood cancers. Currently, several NK cell therapy candidates are undergoing clinical trials, with significant successes, including improved overall survival rates and fewer side effects compared to conventional therapies. NK cells play a vital role in the treatment and potential cure of both solid tumors and hematologic cancers, such as acute myeloid leukemia and multiple myeloma. Although NK cell therapy has not yet been FDA-approved for any specific cancer, ongoing clinical trials are working to improve its efficacy. Some of the promising NK cell therapies in development include AlloNK (Artiva Biotherapeutics), oNKord (Glycostem Therapeutics), FT522 (Fate Therapeutics Inc.), IDP-023 (Indapta Therapeutics), and SENTI-202 (Senti Biosciences), among others. Get a detailed analysis of how NK cell therapies are changing the dynamics of cancer treatment: https://lnkd.in/gKVnCFa3
